key: cord-0847425-to669ryr
authors: Edouard, S.; Jaafar, R.; Orain, N.; Parola, P.; Colson, P.; La Scola, B.; Fournier, P.-E.; Raoult, D.; Drancourt, M.
title: Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies.
date: 2020-11-30
journal: nan
DOI: 10.1101/2020.11.26.20238733
sha: 798c99648cd3f6f8eb628431b79637101e550618
doc_id: 847425
cord_uid: to669ryr

ELISA and chemiluminescence serological assays for COVID-19 are currently incorporating only one or two SARS-CoV-2 antigens. We developed an automated Western immunoblotting as a complementary serologic assay for COVID-19. The Jess Simple Western system, an automated capillary-based assay was used, incorporating an inactivated SARS-CoV-2 lineage 20a strain as antigen, and IgT detection. In total, 602 sera were tested including 223 from RT-PCR-confirmed COVID-19 patients, 76 from patients diagnosed with seasonal HCoVs and 303 from coronavirus-negative control sera. We also compared this assay with the EUROIMMUN(R) SARS-CoV-2 IgG ELISA kit. Among 223 sera obtained from RT-PCR-confirmed COVID-19 patients, 180/223 (81%) exhibited reactivity against the nucleocapsid and 70/223 (31%) against the spike protein. Nucleocapsid reactivity was further detected in 9/76 (14%) samples collected from patients diagnosed with seasonal HCoVs and in 15/303 (5%) coronavirus-negative control samples. In the subset of sera collected more than 2 weeks after the onset of symptoms, the sensitivity was 94% and the specificity 93%, the latter value probably reflecting cross-reactivity of SARS-CoV-2 with other coronaviruses. The automated Western immunoblotting presented a substantial agreement (90%) with the compared ELISA (Cohen's Kappa=0.64). Automated Western immunoblotting may be used as a second line test to monitor exposition of people to HCoVs including SARS-CoV-2.

To date, seven coronaviruses have been reported as human pathogens, 43 including four seasonal coronaviruses (Alphacoronavirus 229E and NL63 and 44 Betacoronavirus HKU1 and OC43) here referred to as HCoVs, which are associated 

Serological assays used to explore exposition to seasonal HCoVs have 53 previously indicated cross-immunity between all coronaviruses (4-6). SARS-CoV-2 54 exhibits several antigens eliciting a serological response in COVID-19 patients, 55 including spike glycoprotein, its N-terminal (S1) and C-terminal (S2) subunits as well 56 as nucleocapsid (7). Most of routinely used serological COVID-19 assays 57 incorporated only one recombinant protein (8) (9) (10) . Second generation assays are 58 combining two antigens to increase sensitivity and mostly specificity (7, 11). 59 NL63 (n=19), HCoV-OC43 (n=21), HCoV-229E (n=8) and HCoV-HKU1 (n=28)) and 92 were collected at least 2 weeks after the diagnosis, of which 45 were also tested by 93 ELISA. A fourth group of 266 sera was collected from children and adults admitted in 94 surgery departments (n=145) and other medical units (=121) before the pandemic, of 95 which 88 serum samples were also tested by ELISA; their HCoVs status was 96 unknown. Altogether, 197 sera tested by ELISA, included 27 sera from COVID-19-97 positive patients and 170 from COVID-19-negative patients. All sera were 98 retrospectively tested and no sample was collected specifically for this study which 99 was approved by our institution's ethics committee under No.2020-024.

Virus growth, purification and concentration. The SARS-CoV-2 IHUMI2 strain 102 (lineage 20a) was used as antigen as previously described (13). One liter of infected 103 cells was collected and clarified by centrifugation at 700 x g for 10 min and by 104 filtering the supernatant through a 0.45-µm pore-sized filter and further a 0.2-µm 105 pore-sized filter. Virions were then aggregated by overnight precipitation at 4ºC with was achieved by ultracentrifugation at 100,000 x g for 90 min at 4°C followed by two perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 30, 2020. ; https://doi.org /10.1101/2020.11.26.20238733 doi: medRxiv preprint viral antigens, we followed the manufacturer's standard method for 12-230-kDa Jess (Table 4) . perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 30, 2020. ; https://doi.org /10.1101 /10. /2020 mainly supported by SARS-CoV-2 nucleocapsid (in 92% of cross-reacting serum 241 samples); and mostly found in adult patients older than 46 years (accounting for 52% 242 of sera with cross-reactivity). Our observations are consistent with previous reports 243 that cross-reactions were observed with nucleocapsid while serological assays 244 incorporating the spike protein have been reported to be more specific but less 245 sensitive (4-6, 15-18). Cross-reactivity has been described between endemic In conclusion, the herein described AWB may be incorporated as a first line 263 serological test for the diagnosis of exposure to SARS-CoV-2 if limited series have to 264 be investigated; or as a second-line assay to confirm or exclude the diagnosis of 265 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 30, 2020. ; https://doi.org /10.1101 /10. /2020 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 30, 2020. ; https://doi.org /10.1101 /10. /2020 DAT. 2020. A systematic review of antibody mediated immunity to 373 coronaviruses: kinetics, correlates of protection, and association with severity. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 30, 2020. ; https://doi.org /10.1101 /10. /2020 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 30, 2020. ; Table 1 . Automated Western immunoblotting results of 27 sera from COVID-19-positive patients and 37 sera from negative controls used to fix automated Western immunoblotting parameters. (Results expressed as median with 25 and 75 percentile).

Negative controls (n=37) sera from COVID-19-positive patients (n=27) Early sera from COVID-19positive patients (n=10) sera from negative HCoVs patients collected before the pandemic (n=13) sera from healthcare workers highly exposed to SARS-CoV-2 (n=14) All

Antibody Profiles in Mild and Severe Cases of COVID-19

Magnitude and kinetics of anti-SARS-CoV-2 antibody 334 responses and their relationship to disease severity

Rapid viral diagnosis and ambulatory management of 340 Nucleocapside

AUC= area under the curve. (n=37) 3 (8%) 0 Early sera from COVID-19 positive patients (n=10) 1 (10%) 0 Sera from healthcare workers highly exposed to SARS-CoV-2 (n=14) 2 (14%) 0 Sera from negative HCoVs patients collected before the pandemic (n=13) 0 0 Sera from patients diagnosed with others HCoVs (n=45) 6 (13%) 0 Sera collected before the pandemic from patients with unknown status for HCoVs (n=88) 5 (6%) 6 (7%)